title: Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana.
abstract: Current clinical trials evaluating new treatment options for non-Hodgkin lymphoma (NHL) are numerous. Studies are comparing traditional chemotherapy with high-dose regimens; various rituximab-based combinations for upfront therapy, many with newly developed drugs; new agents for rituximab-refractory patients; and other approaches. Several intriguing studies were presented at the 2009 annual meeting of the American Society of Hematology (ASH). The efficacy of bendamustine plus rituximab for the first-line treatment of advanced follicular, indolent, and mantle cell lymphomas was the most important finding presented. Other important results included the lack of superiority of high-dose chemotherapy plus rituximab compared with traditional chemotherapy plus rituximab for high-risk patients with aggressive B-cell lymphomas, and promising outcomes with the combination of lenalidomide plus rituximab for both rituximab-refractory and non-rituximab-refractory indolent NHL. The crucial data presented at the 2009 ASH annual meeting are discussed and evaluated by 2 leading experts in the treatment of NHL, Drs. Myron S. Czuczman and Mathias J. Rummel.
authors.affiliation: Lymphoma/Myeloma Service, Lymphoma Translational Research Laboratory, Roswell Park Cancer Institute, Buffalo, New York, USA.
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Mathias J
authors.initials: MJ
authors.lastname: Rummel
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D017326:Clinical Trials, Phase III as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride